Treating advanced breast cancer based on treatment response
Part of Cancer, Skin clinical trials.
This trial tests a personalized approach to treating breast cancer that has spread to nearby lymph nodes. Your surgery and radiation will be tailored to how well your cancer responds to initial chemotherapy or hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have been newly diagnosed with breast cancer that has spread to lymph nodes near your collarbone or inside your chest.
- You are planning to receive chemotherapy or hormone therapy before surgery, followed by breast surgery.
- Your cancer has not spread to distant organs like your lungs or liver.
- You do not have other serious medical conditions, such as recent heart attack or uncontrolled heart or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a personalized approach to treatment after chemotherapy can improve outcomes for people with HER2-positive or triple-negative breast cancer. It aims to tailor further therapy based on how well the tumor responds initially.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests new treatment given before surgery for certain stage IIb–IIIc breast cancers. It uses results from your tumor to guide the treatment plan and aims to improve how well the therapy works before the operation.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.